Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that, effective July 11, 2022, William Burke has been appointed to its Board...
AxoGen, Inc. (AXGN) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Erick DeVinney - VP of Peripheral Nerve Science & Clinical Innovation Conference Call Partici...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: AxoGen, Inc. 2022 Q1 - Results - Earnings Call Presentation
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX) +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. ...
Axogen (NASDAQ:AXGN) stock rose pre-market May 5 after the company Q1 revenue beat analysts' estimates a day ago. Q1 revenue remained largely flat Y/Y to $31M. The company said that excluding Avive revenue of $1.7M in Q1 2021, revenue in Q1 2022 increased 6%. Axogen (AXGN) noted that it had...
AxoGen press release (NASDAQ:AXGN): Q1 Non-GAAP EPS of -$0.20 misses by $0.05. Revenue of $31M (-0.1% Y/Y) beats by $0.66M. The Company continues to expect 2022 revenue will be in the range of $135.0 million to $142.0 million vs. $137.94M consensus. This represents approximately 10% to 1...
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March...
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced topline results from its RECON Clinical Study comparing Avance Nerve Gra...
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May ...
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today published its inaugural Environmental, Social, and Governance (ESG) report highlighti...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...